探索西班牙报告中经济评估的采用情况,将药物定位为公共补偿
Laura Vallejo-Torres1, Juan Oliva-Moreno2,3, Félix Lobo4,5
1Department of Quantitative Methods in Economics and Management,Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Health economics, policy, and law
|December 12, 2024
概括
尽管进行了改革,西班牙治疗定位报告 (IPT) 中的经济评估 (EEs) 仍然很低. 只有10.5%的报告包含了EEs,方法具有显著的异质性,突出了改善药物效率评估的需要.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 卫生技术评估 卫生技术评估
背景情况:
- 治疗定位报告 (IPT) 对西班牙药物融资和定价至关重要.
- 2020年的一项行动计划要求将经济评估 (EE) 纳入IPT.
- 本研究评估了这项改革的最初两年实施情况.
研究的目的:
- 检查EE在西班牙IPT改革后的整合情况.
- 为了比较IPT中EEs中使用的方法.
- 确定改善药物效率评估的挑战和机会.
主要方法:
- 在2021年6月至2023年7月期间发表的181个IPT的系统审查.
- 识别和分析包含经济评估 (EE) 的报告.
- 根据国际标准对EE方法的评估.
主要成果:
- 181个IPT中只有19个 (10.5%) 包含了EE部分.
- 其中六个没有执行 de novo EE,四个仅使用成本最小化.
- 六个IPT采用了与国际标准一致的方法,显示出显著的异质性.
- 在IPT中EEs的总体吸收率仍然很低.
结论:
- 在西班牙的IPT中,EEs的整合率目前很低,而且不一致.
- 在西班牙,有必要加强对药物效率的评估.
- 从这个试点阶段吸取的经验教训对于未来的政策改进至关重要.
相关概念视频
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Bioequivalence: Overview
923
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
923
Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Analysis of Population Pharmacokinetic Data
232
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
232
Drug Control Governance: Regulatory Bodies and Their Impact
141
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
141


